https://orcid.org/0000-0001-7486-4192
Figures
Abstract
Background
The development of specific immunoglobulins to COVID-19 after natural infection or vaccination has been proposed. The efficacy and dynamics of this response are not clear yet.
Aim
This study aims to analyze the immunoglobulins response among COVID-19 patients, COVID-19 vaccine recipients and random individuals.
Methods
A total of 665 participants including 233 COVID-19 patients, 288 COVID-19 vaccine recipients, and 144 random individuals were investigated for anti-COVID-19 immunoglobulins (IgA, IgG, IgM).
Results
Among COVID-19 patients, 22.7% had detectable IgA antibodies with a mean of 27.3±57.1 ng/ml, 29.6% had IgM antibodies with a mean of 188.4±666.0 BAU/ml, while 59.2% had IgG antibodies with a mean of 101.7±139.7 BAU/ml. Pfizer-BioNTech vaccine recipients had positive IgG in 99.3% with a mean of 515.5±1143.5 BAU/ml while 85.7% of Sinopharm vaccine recipients had positive IgG with a mean of 170.0±230.0 BAU/ml. Regarding random individuals, 54.9% had positive IgG with a mean of 164.3±214 BAU/ml. The peak IgM response in COVID-19 patients was detected early at 15–22 days, followed by IgG peak at 16–30 days, and IgA peak at 0–60 days. IgM antibodies disappeared at 61–90 days, while IgG and IgA antibodies decreased slowly after the peak and remained detectable up to 300 days. The frequency of IgG positivity among patients was significantly affected by increased age, admission department (inpatient or outpatient), symptoms, need for oxygen therapy, and increased duration between positive COVID-19 RT PCR test and serum sampling (p˂0.05). Positive correlations were noted between different types of immunoglobulins (IgG, IgM, and IgA) among patients.
Conclusions
Natural infection and COIVD-19 vaccines provide IgG-mediated immunity. The class, positivity, mean, efficacy, and duration of immunoglobulins response are affected by the mechanism of immunity and host related variables. Random community individuals had detectable COVID-19 IgG at ~55%, far from reaching herd immunity levels.
Citation: Al-Tamimi M, Tarifi AA, Qaqish A, Abbas MM, Albalawi H, Abu-Raideh J, et al. (2023) Immunoglobulins response of COVID-19 patients, COVID-19 vaccine recipients, and random individuals. PLoS ONE 18(2): e0281689. https://doi.org/10.1371/journal.pone.0281689
Editor: Nupur Gangopadhyay, CCAC, UNITED STATES
Received: October 17, 2022; Accepted: January 29, 2023; Published: February 14, 2023
Copyright: © 2023 Al-Tamimi et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Data Availability: All relevant data are within the paper and its Supporting information files.
Funding: This work was supported by the Scientific Research and Innovation Support Fund, Ministry of Higher Education and Research, Jordan. Grant Number: cor-MPH/1/5/2020 Principal investigator Mohammad Al-Tamimi The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: The authors have declared that no competing interests exist.
Introduction
An outbreak of the novel (new) coronavirus was first reported in December 2019 in Wuhan, Hubei Province, China. In March 2020, coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was declared as pandemic by the World Health Organization (WHO). With the emergence of many variants, SARS-CoV-2 spread continued leading to the greatest hardship of public health, social development, and economy in our times. As of February 10, 2022, there have been more than 400 million cases worldwide with over 5.5 million deaths [1, 2].
SARS-CoV-2 is the newest member of the Betacoronavirus family, which also includes the causative agents of SARS-CoV and Middle East respiratory syndrome virus (MERS) [3]. Four essential proteins are encoded by the 30 Kb +ve strand RNA genome of the virus: S: spike, N: nucleocapsid, M: membrane and E: envelope, in addition to 15 non-structural proteins (Nsp1-10 and Nsp12-16), and 8 accessory proteins [4, 5].
The S protein is of special importance as it mediates attachment and subsequent viral entry into the target cell. The receptor binding domain (RBD) of the S1 subunit mediates attachment to the membrane of a host cell through binding to angiotensin-converting enzyme 2 (ACE2). The S2 subunit mediates membrane fusion allowing viral entry [6, 7]. Hence, S has been the main target for the development of vaccines and immuno-therapeutics [8].
Antibodies (Abs) specific to SARS-CoV-2 have been extensively studied in the course of natural infection as well as vaccination. Immunoglobulin A (IgA), immunoglobulin M (IgM), and immunoglobulin G (IgG) against S and N proteins of SARS-CoV-2 evolve rapidly within 1 to 2 weeks after symptoms onset in the sera of COVID-19 patients [9–12]. Specific COVID-19 IgG antibodies continue to rise months after infection and would possibly remain active for more than a year [13]. Disease severity proved to reflect on titers and kinetics of the COVID-19 Ab response. It has been repeatedly reported that asymptomatic and mildly symptomatic cases have markedly lower serum Ab titers that wane more rapidly compared to symptomatic patients [14, 15]. On the other hand, the potential development of acute respiratory distress syndrome (ARDS), proved to correlate very strongly with higher Ab titers, especially against the N protein [16]. Interestingly, it was reported that deceased patients show slower appearance of Abs in their sera although titers reach higher levels later in disease progress [17, 18].
Antigen specific IgA response appears to be stronger and more persistent than the IgM response [19]. IgA was found to be predominant in the early phase of SARS-CoV-2 infection in sera and it remained for a longer period in mucosal surfaces of patients [20]. IgA from sera, saliva and bronchoalveolar lavages of patients proved to be more potent in viral neutralization compared to IgG. Interestingly, IgA dimers at the mucosal surfaces showed to be 15 times more potent in virus neutralization than serum IgA monomers [21]. This suggests that IgA Abs might have an important role in preventing infection, transmission and worsening of symptoms.
Specific immunity after COVID-19 vaccination has been documented. Most reports revealed that IgG levels were significantly higher in mRNA vaccinated groups compared to naturally infected patients. On the other hand, IgG levels in vaccinees who took inactivated virus vaccines were more similar to those of natural infection [22–26].
COVID-19 mRNA vaccines also elicit antigen-specific IgA levels and kinetics similar to naturally infected patients [27]. However, only one study reported the IgA response in inactivated virus vaccinees. This study stated that, in contrast to mRNA based Comirnaty, the inactivated virus CoronaVac did not elicit detectable IgA in the nasal mucosa, but both showed detectable serum IgA [28].
The efficacy, kinetics, and protection after natural and vaccine-induced COVID-19 immunity are not fully understood. Specific antibodies play essential role in COVID-19 protection through neutralization and clearance effects. In this study we aimed to investigate the frequency, titer, efficacy, and kinetics of immunoglobulins response (IgG, IgM, and IgA) of COVID-19 patients, COVID-19 vaccine recipients and random individuals.
Materials and methods
Study design
The sampled population included randomized Jordanian individuals who have been infected with COVID-19 confirmed by RT-PCR from May 2020 to August 2021. Participants were recruited at Prince Hamza Hospital (PHH) inpatient or outpatient departments. Demographic and clinical data were collected after obtaining a voluntary consent. Each participant then provided a serum sample for immunological studies of COVID-19 antibodies including IgA, IgM, and IgG. The duration between positive RT-PCR test and serum samples collection was calculated as days.
The details of COVID-19 vaccinated individuals were previously reported [22, 29]. Briefly, Pfizer-BioNTech vaccine recipients (n = 141), and Sinopharm vaccine recipients (n = 147) had serum collected 2 weeks after administration of the second dose. Serum samples were assayed for COVID-19 IgG and IgM antibodies [22]. Finally, 144 random individuals were recruited to determine community prevalence of COVID-19 immunoglobulins. Serum samples referred to PHH labs for non-COVID related studies were collected in the period between 1 September 2021 to 1 October 2021. These samples would presumably include symptomatic and asymptomatic COVID-19 infected individuals, vaccinated individuals, and naïve individuals. Only demographic data was collected for this group without clinical or risk factors information. Serum COVID-19 IgG and IgA were then investigated. The study was approved by the institutional review board (IRB) committee at The Hashemite University on 7 March 2020 (No: 1∕5∕2019∕2020) and PHH IRB committee on 15 March 2020 (No: 1/631). All enrolled participants gave a written informed consent prior to participation in this study.
Anti-COVID-19 immunoglobulin’s measurement
Vitek Immuno Diagnostic Assay Systems (VIDAS®, Biomerieux inc., Hazelwood, MO, USA) for SARS-COV-2 are automated qualitative assays that were used for the detection of IgG or IgM Abs specific for SARS-CoV-2 in human serum or plasma (lithium heparin) by utilizing Enzyme Linked Fluorescent Assay (ELFA) technique. These assays combine a two-step sandwich enzyme immunoassay method with a final fluorescence detection (ELFA). IgG Abs are specifically detected by anti-human IgG, which is labeled with alkaline phosphatase, while IgM Abs are specifically detected similarly by anti-human IgM, also labelled with alkaline phosphatase. The intensity of fluorescence is directly proportional to the level of antibody in the studied sample. An index is calculated as a ratio between the relative fluorescence value (RFV) measured in the sample and the RFV obtained for the calibrator, which is humanized recombinant anti-SARS CoV-2 IgG or IgM. The results were first interpreted as positive (index ≥1) or negative (index <1), before being converted into binding antibody units per milliliter (BAU/ml) that correlate with the WHO standard.
For quantitative determination of human anti-SARS-CoV-2 S1 protein (IgA class antibodies) in serum or plasma samples, an ELISA test was used according to manufacturer instructions (MyBioSource Inc, San Diego, CA, USA). Briefly, 96-well plates were coated with SARS-CoV-2 S1 protein. After washing, captured IgA was detected by anti-human IgA monoclonal antibodies conjugated with horse radish peroxidase (HRP). After another washing step, the chromogenic substrate 3,3’,5,5’-tetramethylbenzidine (TMB) was added and the color reaction was stopped by 2M H2SO4. Finally, the absorbance of each well was measured at 450 nm, and readings were converted to concentration (ng/ml) by blotting against a standard curve. All COVID-19 antibody detection assays used in this study are Conformite Europeenne (CE) approved and had a sensitivity and specificity rates over 90%.
Statistical analysis
For statistical analysis, we used the Statistical Package for the Social Sciences (SPSS) version 24.0 (Chicago, IL, USA). After applying descriptive statistics, data were presented as numbers (percent) for categorical variables and mean ± standard deviation (SD) for numeric variables. Chi-squared test and fisher’s exact test were used to compare categorical variables. Correlations between IgG, IgM, and IgA titers were tested using Bivariate Pearson’s correlation test. P-value <0.05 was considered statistically significant.
Results
Demographic and clinical characteristics of study populations
A total of 665 participants were recruited voluntarily in the study including COVID-19 confirmed patients (n = 233) with documented positive COVID-19 RT-PCR test, COVID-19 vaccine recipients (n = 288), and random samples from PHH (n = 144). Regarding COVID-19 patients, the mean age ± SD was 39.3 ± 14.9 years, range from 2 to 80 years, with most patients in the age range of 20–41 years (48.1%). Males accounted for 52.8% while females accounted for 47.2% of participants. 65.7% of patients were outpatients with no or mild symptoms while 34.3% were admitted to hospital due to moderate to severe illness. Only 1.7% of participants were infected twice with COVID-19 and 1.7% were pregnant at time of infection. Most patients have documented COVID-19 related symptoms (64.4%) while 28.3% were asymptomatic. Furthermore, only 10.7% of patients did need oxygen therapy. The duration between infection (positive RT-PCR) and serum sampling (Mean ± SD) was 82.3 ± 72.9 days (Table 1) (S1 Table). A total of 144 random patients were recruited over 30 days with a mean age of 48.1 ± 20.5 years including 67 participants (46.5%) aged 61 to 80 years. Males were 86 (59.7%), 35 (24.3%) were outpatients, and 109 (75.7%) were inpatients (Table 1). The demographic, side effects, and clinical data related to vaccine recipients were reported in detail (Table 1) [22, 29].
Immunoglobulins response of COVID-19 patients, COVID-19 vaccine recipients, and random individuals
Overall, only 22.7% of COVID-19 infected patients had detectable COVID-19 IgA antibodies with a mean of 27.3 ± 57.1 ng/ml, 29.6% had COVID-19 IgM antibodies with a mean of 188.4 ± 666.0 BAU/ml, while 59.2% had positive COVID-19 IgG antibodies with a mean of 101.7 ± 139.7 BAU/ml (Table 2) (S1 Table). Regarding random samples, the percentage of individuals with positive COVID-19 IgG was 54.9% (79/144), with a mean of 164.3 ± 214 BAU/ml (Table 2). Finally, Pfizer-BioNTech vaccine recipients had positive COVID-19 IgG in 99.3% with a mean of 515.5 ± 1143.5 BAU/ml while 85.7% of Sinopharm vaccine recipients had positive IgG with a mean of 170.0 ± 230.0 BAU/ml (Table 2).
The dynamics of immunoglobulins response of COVID-19 patients were studied to determine the peak response of each immunoglobulin in COVID-19 patients (Fig 1). Th peak IgG response in COVID-19 patients was at 16–30 days (183.1 ± 147.9 BAU/ml) (Fig 1A). The peak IgM response in COVID-19 patients was early at 15–22 days (872.3 ± 1634.2 BAU/ml) (Fig 1B). The peak IgA response in COVID-19 patients was at 0–60 days (62.9 ± 104.3 ng/ml) (Fig 1C). IgM antibodies almost disappeared at 61–90 days in all patients, while IgG and IgA antibodies started to decrease slowly after the peak and were still detectable up to 300 days (Fig 1) (S2 Table).
(A) IgG, (B) IgM, and (C) IgA. The black arrow indicates the peak response.
Factors affecting immunoglobulins positive response among COVID-19 patients
The frequency of IgG positivity was significantly affected by increased age (p = 0.02), outpatients (p < 0.001), symptomatic patients (p < 0.001), patients who needed oxygen therapy (p = 0.01), and increased duration between positive COVID-19 RT-PCR test and serum sampling (Table 3). Furthermore, the frequency of IgM positivity was significantly increased in inpatients (p = 0.02), patients who needed oxygen (p = 0.004), and shorter duration between positive COVID-19 RT-PCR test and serum sampling (p = 0.02) (Table 3). There were no factors that had any significant effect on the frequency of IgA positivity among COVID-19 patients (Table 3) (S1 Table).
Correlations between immunoglobulins among COVID-19 patients
IgG titer correlated positively with IgM titer and IgA concentration (p < 0.001) among COVID-19 patients. In addition, IgG positive results were associated significantly with positive IgM and positive IgA results (p < 0.001). Furthermore, IgM titer correlated positively with IgA concentration and was associated with positive results (p < 0.001) (Table 4) (S1 Table).
Discussion
Magnitude and kinetics of humoral immunity in response to SARS-CoV-2 infection give insights into measures of immune protection against natural infection as well as measures of vaccine efficacies. It has been repeatedly reported that most B-cell epitopes identified have been found in the S1 C-terminal domain and S2 [30–32]. In addition, approximately most neutralizing Abs are induced by the RBD (amino acids 306–527) and S2 [33, 34]. Since the S2 protein is more conserved within other corona-viruses, S1 (specifically the RBD) remains the most valuable tool for specific Ab identification [34–44]. Hence, in this study, we measured the presence of S1 specific IgM, IgG and IgA in sera from naturally infected COVID-19 patients, COVID-19 naïve Pfizer and Sinopharm vaccinated personnel, and a group of random individuals.
The positivity and levels of anti-S IgG were found to negatively correlate with age and positively with symptom severity, which is consistent with previous studies [45, 46]. Increased symptoms severity, late Ab response, and elevated viral loads could stand behind the higher Ab concentration in sera of older patients compared to younger ones, especially at longer times (6 months) post infection. Previous studies reported that anti-S Ab titers increased with symptom severity [45, 46]. A significant positive correlation was found between anti-S IgG and patients department. Naturally infected unvaccinated outpatients showed higher Ab responses compared to inpatients. This could be due to variations in blood collection time. Inpatients samples were collected during hospitalization within the first 2 weeks after the onset of COVID-19 symptoms, whereas outpatients donated their samples up to 10 months after.
In the context of vaccination, we found that anti-S IgG levels detected 2 weeks post-vaccination were highest among COVID-19 naïve Pfizer-BioNTech vaccinated individuals consistent with previous investigations, as Pfizer-BioNTech was repeatedly reported to be more effective in immune protection against COVID-19 compared to Sinopharm and natural infection [22–26, 39–41, 47].
IgM is thought to play an important role in protective immunity against COVID-19, as a strong association between declining anti-S IgM levels and declining neutralizing Ab responses was observed [48–50]. Here, we found that the IgM response in naturally infected COVID-19 patients was higher compared to vaccinated individuals in terms of positivity and titers, which is consistent with other studies [42, 50]. Interestingly, Ruggiero et al. [50] reported that COVID-19 naïve individuals vaccinated with Pfizer’s mRNA vaccine showed unconventional patterns of anti-S IgM responses depicted by either absence of IgM, development of IgM after IgG, or simultaneous presence of IgM and IgG. It is hard to speculate the reason behind vaccine induced unconventional IgM responses in potentially COVID-19 naïve vaccinated personnel. One reason for the total absence of IgM two weeks post full vaccination could be the lack of IgM memory response from a pre-existing immunity to cross-reactive human coronaviruses, a previous primary immune response against an asymptomatic infection with the virus, or against first booster of vaccination with expedited IgM decay. Another probable reason could be the adjuvant effect of the lipid components of the vaccine in driving early and extensive IgG class-switching because of the reported Th1-polarized responses [51]. The persistence of virus-specific IgM responses in vaccinees could refer to the persistence of non-class-switched IgM+ memory B cells [52].
SARS-CoV-2 S IgA elicited by natural infection mediates viral neutralization and is likely an important component of natural immunity [27, 28]. IgA responses to COVID-19 vaccines have been investigated, especially against mRNA-based vaccines. Chan et. al. reported that COVID-19 mRNA vaccination evokes S specific IgA with similar kinetics compared to S specific IgG but it declines more rapidly in sera of vaccinees following both the 1st and 2nd doses [28].
It has been reported that both mRNA based Comirnaty and inactivated virus CoronaVac induce plasma SARS-CoV-2 S1-specific IgA. However, Comirnaty, but not CoronaVac, was also able to induce S1-specific IgA in the nasal mucosa [28]. mRNA based vaccines also evoked the secretion of anti-S IgA in women milk [53] as well as saliva of vaccinees [54]. Although the intramuscular route of vaccination does not induce mucosal immunity [55], there has been evidence that lipid nanoparticles, such as those harboring the mRNA-based vaccines can be detected in distal tissues, including the lung [56]. Our findings show that IgA levels are higher in naturally infected COVID-19 patients compared to Pfizer and Sinopharm vaccinees and random individuals, indicating that IgA response is more prominent due to natural infections consistent with previous investigations [27, 28].
We find it hard to draw conclusions on our random individual group, as it could represent a variety of infection/vaccination settings including naturally infected-unvaccinated personnel, COVID-19 naïve vaccinees with different types of vaccines (Pfizer, Sinopharm or AstraZeneca) and partial or full vaccination, and vaccinees with previous or concurrent infection. However, the Ab response of this group with ~55% anti-S IgG is still far from reaching herd immunity levels (65–95%) among the Jordanian population [57].
Initial studies during the first wave of COVID-19 spread, before the introduction of vaccines and before probable reinfections, reflected a realistic pattern of immunoglobulins response to SARS-CoV-2 infection. In general, IgM peak response was at 2–4 weeks and became undetectable 3 months post symptoms onset, IgG and IgA antibodies usually follow and peaked at around 30–60 days then decrease slowly with levels still detectable 9 months or later [58–60]. Despite heterogeneity of the sample population, severe COVID-19 cases were always associated with higher Ab production and neutralization titers [60]. A large cohort study on mRNA-based vaccine recipients reported that the IgG response evoked against vaccination for COVID-19 peaked 15 days post second dose and declined over time through six months post vaccination [61]. Despite waning antibody titers over time after vaccination, no cases of severe COVID-19 were detected among participants in another study [62]. The kinetics of COVID-19 immunoglobulins reported in this study are in concordance with previous studies [36–44, 58–62].
Despite the importance of neutralizing Abs in protection against SARS-CoV-2 infection, the other arm of adaptive immunity, namely T cells, has proved to be important for immune protection against COVID-19. Virus specific cytotoxic CD8+T cell response was detected early within 7 days of symptom onset and peaked after 14 days. This proved to correlate with effective viral clearance and milder symptoms. On the other hand, T cell responses were found to be severely impaired in severe and critical cases of COVID-19. This impairment was found to be associated with intense T cell activation and lymphopenia [60–62].
Conclusions
Specific SARS-CoV-2 anti-S antibodies were detectable in naturally infected, vaccine recipients and random individuals. The class, levels, positivity rate, dynamics and duration of immunoglobulins response varied widely, which reflect immunogenicity and boosting effect at one end and host immune state at the other end. This study highlights the complexity and diversity of factors contributing to COVID-19 immunoglobulins response among community.
Supporting information
S1 Table. Raw data of COVID-19 confirmed patients.
Raw data of study population including demographic data, clinical data, and immunoglobins response (IgG, IgM, and IgA). These data were used to generate Tables 1–4.
https://doi.org/10.1371/journal.pone.0281689.s001
(XLS)
S2 Table. Raw data of immunoglobulins response of COVID-19 confirmed patients over time.
Immunoglobulins titers mean ± SD over time in days was provided and used to generate Fig 1.
https://doi.org/10.1371/journal.pone.0281689.s002
(XLSX)
Acknowledgments
We would like to thank The Hashemite University, the Ministry of Health, the Ministry of Higher Education and Research, and Prince Hamzah Hospital in Jordan for their support.
References
- 1.
https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports.
- 2. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al; China Novel Coronavirus Investigating and Research Team. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med. 2020 Feb 20;382(8):727–733. pmid:31978945
- 3. Coutard B, Valle C, de Lamballerie X, Canard B, Seidah NG, Decroly E. The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade. Antiviral Res. 2020 Apr;176:104742. pmid:32057769
- 4. Wu A, Peng Y, Huang B, Ding X, Wang X, Niu P, et al. Genome Composition and Divergence of the Novel Coronavirus (2019-nCoV) Originating in China. Cell Host Microbe. 2020 Mar 11;27(3):325–328. pmid:32035028
- 5. Bianchi M, Benvenuto D, Giovanetti M, Angeletti S, Ciccozzi M, Pascarella S. Sars-CoV-2 Envelope and Membrane Proteins: Structural Differences Linked to Virus Characteristics? Biomed Res Int. 2020 May 30;2020:4389089. pmid:32596311
- 6. Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT, Veesler D. Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. Cell. 2020 Apr 16;181(2):281–292.e6. Erratum in: Cell. 2020 Dec 10;183(6):1735. pmid:32155444
- 7. Wang Q, Zhang Y, Wu L, Niu S, Song C, Zhang Z, et al. Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2. Cell. 2020 May 14;181(4):894–904.e9. pmid:32275855
- 8. Dai L, Gao GF. Viral targets for vaccines against COVID-19. Nat Rev Immunol. 2021 Feb;21(2):73–82. pmid:33340022
- 9. Wu J, Liang B, Chen C, Wang H, Fang Y, Shen S, et al. SARS-CoV-2 infection induces sustained humoral immune responses in convalescent patients following symptomatic COVID-19. Nat Commun. 2021 Mar 22;12(1):1813. pmid:33753738
- 10. Lei Q, Li Y, Hou HY, Wang F, Ouyang ZQ, et al. Antibody dynamics to SARS-CoV-2 in asymptomatic COVID-19 infections. Allergy. 2021 Feb;76(2):551–561. pmid:33040337
- 11. Vogelzang EH, Loeff FC, Derksen NIL, Kruithof S, Ooijevaar-de Heer P, van Mierlo G, et al. Development of a SARS-CoV-2 Total Antibody Assay and the Dynamics of Antibody Response over Time in Hospitalized and Nonhospitalized Patients with COVID-19. J Immunol. 2020 Dec 15;205(12):3491–3499. pmid:33127820
- 12. Li K, Huang B, Wu M, Zhong A, Li L, Cai Y, et al. Dynamic changes in anti-SARS-CoV-2 antibodies during SARS-CoV-2 infection and recovery from COVID-19. Nat Commun. 2020 Nov 27;11(1):6044. pmid:33247152
- 13. Xiao K, Yang H, Liu B, Pang X, Du J, Liu M, et al. Antibodies Can Last for More Than 1 Year After SARS-CoV-2 Infection: A Follow-Up Study From Survivors of COVID-19. Front Med (Lausanne). 2021 Jul 16;8:684864. pmid:34336891
- 14. Choe PG, Kang CK, Suh HJ, Jung J, Song KH, Bang JH, et al. Waning Antibody Responses in Asymptomatic and Symptomatic SARS-CoV-2 Infection. Emerg Infect Dis. 2021 Jan;27(1):327–9. pmid:33050983
- 15. Kallaste A, Kisand K, Aart A, Kisand K, Peterson P, Lember M. Antibody levels remain high to one-year’s follow-up after moderate and severe COVID-19, but not after mild cases. Infect Dis (Lond). 2021 Dec 24:1–11. pmid:34951554
- 16. Batra M, Tian R, Zhang C, Clarence E, Sacher CS, Miranda JN, et al. Role of IgG against N-protein of SARS-CoV2 in COVID19 clinical outcomes. Sci Rep. 2021 Feb 10;11(1):3455. pmid:33568776
- 17. Lucas C, Klein J, Sundaram M, Liu F, Wong P, Silva J, et al. Kinetics of antibody responses dictate COVID-19 outcome. medRxiv [Preprint]. 2020 Dec 22:2020.12.18.20248331. pmid:33398304
- 18. Lynch KL, Whitman JD, Lacanienta NP, Beckerdite EW, Kastner SA, Shy BR, et al. Magnitude and Kinetics of Anti-Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Responses and Their Relationship to Disease Severity. Clin Infect Dis. 2021 Jan 27;72(2):301–308. pmid:33501951
- 19. Ibarrondo FJ, Fulcher JA, Goodman-Meza D, Elliott J, Hofmann C, Hausner MA, et al. Rapid decay of anti–SARS-CoV-2 antibodies in persons with mild Covid-19. New England Journal of Medicine. 2020;383(11):1085–7. pmid:32706954
- 20. Sterlin D, Mathian A, Miyara M, Mohr A, Anna F, Claër L, et al. IgA dominates the early neutralizing antibody response to SARS-CoV-2. Sci Transl Med. 2021 Jan 20;13(577):eabd2223. pmid:33288662
- 21. Wang Z, Lorenzi JCC, Muecksch F, Finkin S, Viant C, Gaebler C, et al. Enhanced SARS-CoV-2 neutralization by dimeric IgA. Sci Transl Med. 2021 Jan 20;13(577):eabf1555. pmid:33288661
- 22. Alqassieh R, Suleiman A, Abu-Halaweh S, Santarisi A, Shatnawi O, Shdaifat L, et al. Pfizer-BioNTech and Sinopharm: A Comparative Study on Post-Vaccination Antibody Titers. Vaccines (Basel). 2021 Oct 21;9(11):1223. pmid:34835153
- 23. Wang Z, Schmidt F, Weisblum Y, Muecksch F, Barnes CO, Finkin S, et al. mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants. Nature. 2021 Apr;592(7855):616–622. pmid:33567448
- 24. Azak E, Karadenizli A, Uzuner H, Karakaya N, Canturk NZ, Hulagu S. Comparison of an inactivated Covid19 vaccine-induced antibody response with concurrent natural Covid19 infection. Int J Infect Dis. 2021 Dec;113:58–64. pmid:34597764
- 25. Jackson LA, Anderson EJ, Rouphael NG, Roberts PC, Makhene M, Coler RN, et al; mRNA-1273 Study Group. An mRNA Vaccine against SARS-CoV-2—Preliminary Report. N Engl J Med. 2020 Nov 12;383(20):1920–1931. pmid:32663912
- 26. Sahin U, Muik A, Derhovanessian E, Vogler I, Kranz LM, Vormehr M, et al. COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses. Nature. 2020 Oct;586(7830):594–599. Erratum in: Nature. 2021 Feb;590(7844):E17. pmid:32998157
- 27. Wisnewski AV, Campillo Luna J, Redlich CA. Human IgG and IgA responses to COVID-19 mRNA vaccines. PLoS One. 2021 Jun 16;16(6):e0249499. pmid:34133415
- 28. Chan RWY, Liu S, Cheung JY, Tsun JGS, Chan KC, Chan KYY, et al. The Mucosal and Serological Immune Responses to the Novel Coronavirus (SARS-CoV-2) Vaccines. Front Immunol. 2021 Oct 12;12:744887. pmid:34712232
- 29. Abu-Halaweh S, Alqassieh R, Suleiman A, Al-Sabbagh MQ, AbuHalaweh M, AlKhader D, et al. Qualitative Assessment of Early Adverse Effects of Pfizer-BioNTech and Sinopharm COVID-19 Vaccines by Telephone Interviews. Vaccines (Basel). 2021 Aug 26;9(9):950. pmid:34579187
- 30. Li Y, Lai DY, Zhang HN, Jiang HW, Tian X, Ma ML, et al. Linear epitopes of SARS-CoV-2 spike protein elicit neutralizing antibodies in COVID-19 patients. Cell Mol Immunol. 2020 Oct;17(10):1095–1097. pmid:32895485
- 31. Mishra N, Huang X, Joshi S, Guo C, Ng J, Thakkar R, et al. Immunoreactive peptide maps of SARS-CoV-2. Commun Biol. 2021 Feb 12;4(1):225. Erratum in: Commun Biol. 2021 Mar 9;4(1):339. pmid:33580175
- 32. Yi Z, Ling Y, Zhang X, Chen J, Hu K, Wang Y, et al. Functional mapping of B-cell linear epitopes of SARS-CoV-2 in COVID-19 convalescent population. Emerg Microbes Infect. 2020 Dec;9(1):1988–1996. pmid:32844713
- 33. Piccoli L, Park YJ, Tortorici MA, Czudnochowski N, Walls AC, Beltramello M, et al. Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology. Cell. 2020 Nov 12;183(4):1024–1042.e21. pmid:32991844
- 34. Shah P, Canziani GA, Carter EP, Chaiken I. The Case for S2: The Potential Benefits of the S2 Subunit of the SARS-CoV-2 Spike Protein as an Immunogen in Fighting the COVID-19 Pandemic. Front Immunol. 2021 Mar 9;12:637651. pmid:33767706
- 35. Premkumar L, Segovia-Chumbez B, Jadi R, Martinez DR, Raut R, Markmann A, et al. The receptor binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients. Sci Immunol. 2020 Jun 11;5(48):eabc8413. pmid:32527802
- 36. Marcotte H, Piralla A, Zuo F, Du L, Cassaniti I, Wan H, et al. Immunity to SARS-CoV-2 up to 15 months after infection. iScience. 2022 Feb 18;25(2):103743. pmid:35018336
- 37. Peghin M, De Martino M, Fabris M, Palese A, Visintini E, Graziano E, et al. The Fall in Antibody Response to SARS-CoV-2: a Longitudinal Study of Asymptomatic to Critically Ill Patients Up to 10 Months after Recovery. J Clin Microbiol. 2021 Oct 19;59(11):e0113821. pmid:34379530
- 38. Wang H, Yuan Y, Xiao M, Chen L, Zhao Y, Haiwei Zhang, et al. Dynamics of the SARS-CoV-2 antibody response up to 10 months after infection. Cell Mol Immunol. 2021 Jul;18(7):1832–1834. pmid:34099890
- 39. Lin DY, Gu Y, Wheeler B, Young H, Holloway S, Sunny SK, et al. Effectiveness of Covid-19 Vaccines over a 9-Month Period in North Carolina. N Engl J Med. 2022 Mar 10;386(10):933–941. pmid:35020982
- 40. Tartof SY, Slezak JM, Fischer H, Hong V, Ackerson BK, Ranasinghe ON, et al. Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study. Lancet. 2021 Oct 16;398(10309):1407–1416. pmid:34619098
- 41. Zhang S, Xu K, Li C, Zhou L, Kong X, Peng J, et al. Long-Term Kinetics of SARS-CoV-2 Antibodies and Impact of Inactivated Vaccine on SARS-CoV-2 Antibodies Based on a COVID-19 Patients Cohort. Front Immunol. 2022 Jan 27;13:829665. pmid:35154152
- 42. Wang Z, Schmidt F, Weisblum Y, Muecksch F, Barnes CO, Finkin S, et al. mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants. Nature. 2021 Apr;592(7855):616–622. pmid:33567448
- 43. Hirotsu Y, Amemiya K, Sugiura H, Shinohara M, Takatori M, Mochizuki H, et al. Robust Antibody Responses to the BNT162b2 mRNA Vaccine Occur Within a Week After the First Dose in Previously Infected Individuals and After the Second Dose in Uninfected Individuals. Front Immunol. 2021 Aug 26;12:722766. pmid:34512649
- 44. Narowski TM, Raphel K, Adams LE, Huang J, Vielot NA, Jadi R, et al. SARS-CoV-2 mRNA vaccine induces robust specific and cross-reactive IgG and unequal neutralizing antibodies in naive and previously infected people. Cell Rep. 2022 Feb 1;38(5):110336. pmid:35090596
- 45. Efrati S, Catalogna M, Abu Hamed R, Hadanny A, Bar-Chaim A, Benveniste-Levkovitz P, et al. Early and long term antibody kinetics of asymptomatic and mild disease COVID-19 patients. Sci Rep. 2021 Jul 2;11(1):13780. pmid:34215811
- 46. Luo C, Liu M, Li Q, Zheng X, Ai W, Gong F, et al. Dynamic changes and prevalence of SARS-CoV-2 IgG/IgM antibodies: Analysis of multiple factors. Int J Infect Dis. 2021 Jul;108:57–62. pmid:33932603
- 47. Qaqish A, Abbas MM, Al-Tamimi M, Abbas MA, Al-Omari M, Alqassieh R. SARS-CoV-2 Antinucleocapsid Antibody Response of mRNA and Inactivated Virus Vaccines Compared to Unvaccinated Individuals. Vaccines (Basel). 2022 Apr 20;10(5):643. pmid:35632399
- 48. Harrington WE, Trakhimets O, Andrade DV, Dambrauskas N, Raappana A, Jiang Y, et al. Rapid decline of neutralizing antibodies is associated with decay of IgM in adults recovered from mild COVID-19. Cell Rep Med. 2021 Apr 20;2(4):100253. pmid:33842901
- 49. Prévost J, Gasser R, Beaudoin-Bussières G, Richard J, Duerr R, Laumaea A, et al. Cross-Sectional Evaluation of Humoral Responses against SARS-CoV-2 Spike. Cell Rep Med. 2020 Oct 20;1(7):100126. pmid:33015650
- 50. Ruggiero A, Piubelli C, Calciano L, Accordini S, Valenti MT, Carbonare LD, et al. SARS-CoV-2 vaccination elicits unconventional IgM specific responses in naïve and previously COVID-19-infected individuals. EBioMedicine. 2022 Mar;77:103888. pmid:35196644
- 51. Röltgen K, Nielsen SCA, Arunachalam PS, Yang F, Hoh RA, Wirz OF, et al. mRNA vaccination compared to infection elicits an IgG-predominant response with greater SARS-CoV-2 specificity and similar decrease in variant spike recognition. medRxiv [Preprint]. 2021 Apr 7:2021.04.05.21254952. pmid:33851181
- 52. Bohannon C, Powers R, Satyabhama L, Cui A, Tipton C, Michaeli M, et al. Long-lived antigen-induced IgM plasma cells demonstrate somatic mutations and contribute to long-term protection. Nat Commun. 2016 Jun 7;7:11826. Erratum in: Nat Commun. 2016 Aug 16;7:12687. Lee, Francis Eun-Hyung [Lee, Frances Eun-Hyung]. pmid:27270306
- 53. Selma-Royo M, Bäuerl C, Mena-Tudela D, Aguilar-Camprubí L, Pérez-Cano FJ, Parra-Llorca A, et al. Anti-SARS-CoV-2 IgA and IgG in human milk after vaccination is dependent on vaccine type and previous SARS-CoV-2 exposure: a longitudinal study. Genome Med. 2022 Apr 21;14(1):42. pmid:35449030
- 54. Sheikh-Mohamed S, Isho B, Chao GYC, Zuo M, Cohen C, Lustig Y, et al. Systemic and mucosal IgA responses are variably induced in response to SARS-CoV-2 mRNA vaccination and are associated with protection against subsequent infection. Mucosal Immunol. 2022 Apr 25:1–10. pmid:35468942
- 55. Zheng B, Peng W, Guo M, Huang M, Gu Y, Wang T, et al. Inhalable nanovaccine with biomimetic coronavirus structure to trigger mucosal immunity of respiratory tract against COVID-19. Chem Eng J. 2021 Aug 15;418:129392. pmid:33762883
- 56. Bahl K, Senn JJ, Yuzhakov O, Bulychev A, Brito LA, Hassett KJ, et al. Preclinical and Clinical Demonstration of Immunogenicity by mRNA Vaccines against H10N8 and H7N9 Influenza Viruses. Mol Ther. 2017 Jun 7;25(6):1316–1327. pmid:28457665
- 57.
Charumilind S, Craven M, Lamb J, Sabow A, Singhal S, Wilson M. When will the COVID-19 pandemic end? Designed by McKinsey Global Publishing, 2022. https://www.mckinsey.com/industries/healthcare-systems-and-services/our-insights/when-will-the-covid-19-pandemic-end.
- 58. Siracusano G, Brombin C, Pastori C, Cugnata F, Noviello M, Tassi E, et al. Profiling Antibody Response Patterns in COVID-19: Spike S1-Reactive IgA Signature in the Evolution of SARS-CoV-2 Infection. Front Immunol. 2021 Nov 3;12:772239. pmid:34804064
- 59. Siracusano G, Pastori C, Lopalco L. Humoral Immune Responses in COVID-19 Patients: A Window on the State of the Art. Front Immunol (2020) 11:2020.01049. pmid:32574261
- 60. Huang AT, Garcia-Carreras B, Hitchings MDT, Yang B, Katzelnick LC, Rattigan SM, et al. A systematic review of antibody mediated immunity to coronaviruses: kinetics, correlates of protection, and association with severity. Nat Commun. 2020 Sep 17;11(1):4704. pmid:32943637
- 61. Oliveira-Silva J, Reis T, Lopes C, Batista-Silva R, Ribeiro R, Marques G, et al. Long-term serological SARS-CoV-2 IgG kinetics following mRNA COVID-19 vaccine: real-world data from a large cohort of healthcare workers. Int J Infect Dis. 2022 May 11;122:1–7. pmid:35568366
- 62. Coppeta L, Ferrari C, Somma G, Mazza A, D’Ancona U, Marcuccilli F, et al. Reduced Titers of Circulating Anti-SARS-CoV-2 Antibodies and Risk of COVID-19 Infection in Healthcare Workers during the Nine Months after Immunization with the BNT162b2 mRNA Vaccine. Vaccines (Basel). 2022 Jan 18;10(2):141. pmid:35214600